Pfizer bags a hormone-sensitive win
Talapro-3 could help move Talzenna into earlier prostate cancer.
Pfizer touts atirmociclib success
But this comes in second-line breast cancer, a use the group isn’t pursuing.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
Roche follows Pfizer out of LTβR
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
